At the same time that Bayer AG is waging an aggressive legal battle to overturn significant verdicts against them, the company has reportedly reached agreements with other Roundup cancer victims who have been diagnosed with non-Hodgkin’s lymphoma. According to pre-settlement funding firm Legal-Bay LLC, a portion of those who are seeking compensation from the chemical company will see a resolution to their claims.
At the heart of the issue is glyphosate, the main ingredient in the world’s most popular weed killer and the purported cause of Roundup cancer. Several lawsuits have already been heard against Monsanto. One federal jury ordered the company to pay $80 million to a man who had used the product for over thirty years on his 56-acre property, and another jury awarded a groundskeeper diagnosed with cancer almost $300 million dollars. That verdict was later reduced to just under $80 million. Both of those decisions are currently under appeal.
Financial Terms Not Yet Known in Roundup Cancer Settlements
Though Legal-Bay indicated that they’d been notified of a settlement, they had no information as to how much Roundup cancer patients and Bayer AG had agreed to. They also were not sure of exactly how many of the 80,000 pending claims the settlement will resolve, but they were able to confirm that there will be categories of claimants that divide them into tears of the severity of their damages. All of those included in the resolution are apparently Americans, leaving many to wonder whether others will eventually seek similar remedies. Glyphosate has already been either banned or restricted in over two dozen countries.
In the United States, concerns over Roundup cancer have led Los Angeles County to suspend all use of glyphosate products on any county-owned property. In response to the publicity surrounding the allegations that their product causes cancer, Bayer insists that the product has been thoroughly tested that it can be used safely and is not carcinogenic.